SCHEMBL2356050

SCHEMBL2356050

COc1cc(OC(=O)c2cccnc2OC)ccc1-c1ccc2c(c1C(OC=O)c1ccc(C)s1)C(C)=CC(C)(C)N2

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
TP53 P04637 2/20 0.40
HTT P42858 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HSD17B10 Q99714 1/20 0.40
NR3C1 P04150 15/20 0.35
NR3C2 P08235 1/20 0.35
AR P10275 1/20 0.35
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
DRD1 P21728 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PGR P06401 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4428816 0.86 MAPT (0.44) MAPTLMNATP53HTTNPSR1
SCHEMBL17667953 0.84 NR3C1 (0.47) MAPTLMNATP53HTTNPSR1
SCHEMBL17667944 0.83 MAPT (0.39) MAPTLMNATP53HTTNPSR1
SCHEMBL2346391 0.82 MAPT (0.41) MAPTLMNATP53HTTNPSR1
SCHEMBL2354781 0.82 MAPT (0.46) MAPTLMNATP53HTTNPSR1
SCHEMBL2544665 0.82 MAPT (0.40) MAPTLMNATP53HTTNPSR1
SCHEMBL2354785 0.82 MAPT (0.36) MAPTLMNATP53HTTNPSR1
SCHEMBL1781318 0.81 MAPT (0.41) MAPTLMNATP53HTTNPSR1
SCHEMBL2350291 0.80 MAPT (0.39) MAPTLMNATP53HTTNPSR1
SCHEMBL2355746 0.79 MAPT (0.44) MAPTLMNATP53HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008497-B2 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 US disclosed
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS NR3C1, NR3C2, NR5A1 MAPT 4861/4885LMNA 4460/4885TP53 4197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.